- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Asthma
- Meeting Date: November 2025
- Public Summary Document (PSD) November 2025 PBAC Meeting - (PDF 1.4MB)
- Public Summary Document (PSD) November 2025 PBAC Meeting - (Word 506.0KB)
Tezepelumab – November 2025
Tezepelumab: Solution for injection 210 mg in 1.91 mL single dose pre-filled pen (110 mg per mL); Tezspire® - November 2025
Last updated
5 November 2025